Researchers at Winship Cancer Institute of Emory University have been awarded up to $17.6 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop innovative technology aimed at improving outcomes for patients with cancer requiring surgery. The project, titled "MarginCall," is set to transform how surgical margins are evaluated during cancer surgeries, with an initial focus on breast and ovarian cancer.

Researchers at The University of Kansas Cancer Center are leading a multicenter trial, funded by a nearly $4 million grant from the National Institutes of Health, to tackle food insecurity in people with blood cancers who are receiving transplant or cellular therapy. Memorial Sloan Kettering Cancer Center, Duke University, and Stanford also are participating in the trial, known as NOURISH (Nutrition Outreach in Systems of Healthcare).

David and Janet Greene, parents of Michael Greene, have supported glioma research at Vanderbilt and have made a $1 million donation in their son’s honor for the Brain Tumor Center. In addition, Gladiator Project recently made a $500,000 commitment to establish the Gladiator Project Brain Tumor Research Fund to advance brain tumor clinical research at Vanderbilt-Ingram.

In 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient’s electronic medical record as soon as they become available. As a result of this newer law, many patients are seeing and reading their test results even before their doctor has. The problem is that many medical reports aren’t written with patients in mind.

Two new studies led by Washington University physician-scientist Stephen T. Oh, MD, PhD, at Siteman Cancer Center have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

A new study led by UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought. The study found that nearly half of high-risk prostate cancer patients previously classified as nonmetastatic by conventional imaging actually have metastatic disease when evaluated with advanced prostate-specific membrane antigen–positron emission tomography imaging.

Investigators from Baylor College of Medicine, Texas Children’s Cancer and Hematology Center, the Center for Cell and Gene Therapy at Baylor, Houston Methodist Hospital, and Texas Children’s Hospital examined how molecular dynamics at the immune synapse—where CAR T cells bind to cancer cells—affect anticancer activity.

Keck Medicine of USC is participating in a national, multisite clinical trial examining if a water vapor system that uses small, targeted amounts of steam to kill cancer cells is a safe and effective treatment for prostate cancer.

A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.

Women who develop bacterial vaginosis (BV) often later acquire chlamydia. Now, researchers at Albert Einstein College of Medicine, Roswell Park Comprehensive Cancer Center, and the Icahn School of Medicine at Mount Sinai have found that BV actually consists of two subtypes – one of which significantly increases the risk of developing chlamydia infections.

Compared with other forms of breast cancer, triple-negative breast cancer (TNBC) is more likely to have spread at the time of diagnosis and is more likely to recur, largely because it becomes resistant to chemotherapy. Researchers at Roswell Park Comprehensive Cancer Center have identified a previously unknown cause of resistance to doxorubicin, a mainstay of treatment for TNBC.

A non-opioid investigational drug with promising pre-clinical results in treating neuropathic pain has passed an important hurdle after the study’s safety review committee reviewed the data from initial volunteers and recommended to progress into the next dose level in a first-in-human clinical trial. The drug, ART26.12, is being developed by Artelo Biosciences, Inc.

Researchers at The Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center, have developed a new tool that could change the way cancer patients are treated. The tool, called SCORPIO, uses artificial intelligence (AI) to predict how well cancer patients will respond to a type of treatment called immune checkpoint inhibitors.

UK Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant cancers by targeting a specific protein modification.

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of the University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.

Mount Sinai scientists have made a breakthrough in treating a type of liver cancer called hepatocellular carcinoma. The research tested a combination of treatments that could help patients live longer without their cancer getting worse. Their Phase III study is titled "LEAP-012: Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma."

A new artificial intelligence (AI) tool developed by Stanford cancer faculty members combines data from medical images with text to predict cancer prognoses and treatment responses.

A first-of-its-kind new cancer test has been developed at the University of Michigan. MyHPVscore is a highly accurate blood test that can detect human papilloma virus-related head and neck cancer by measuring fragments of tumor DNA in a patient’s bloodstream.

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and—due to innovations in manufacturing—could make future cellular immunotherapies less expensive and more accessible to patients, according to a team co-led by Washington University medical oncologist Armin Ghobadi, MD.

Read More

A new study provides insights into how medulloblastoma can arise as the cerebellum develops. Researchers at Baylor College of Medicine, Texas Children’s Cancer Center, University of Toronto, St. Jude Children’s Research Hospital, and Mayo Clinic College of Medicine and Science, discovered that the same gene, ZIC1, can drive highly similar cancers by distinct, context-dependent mechanisms.

Karmanos Cancer Institute has announced that the TheraBionic P1 device, an FDA-approved, at-home treatment, is now available to treat advanced liver cancer. Karmanos is the first institution worldwide to prescribe this treatment.

Huntsman Cancer Institute at the University of Utah hosted a ribbon cutting for its second mobile screening clinic in collaboration with the Utah County Health Department. Peter Huntsman, chairman and CEO of Huntsman Cancer Foundation, spoke at the event.

Karmanos Cancer Institute has cut the ribbon on its 17th clinic, in Dearborn, Michigan. To read an article about the center in Arabic, click here.

Huntsman Cancer Institute at the University of Utah has joined other institutions on an innovative clinical trials program designed to match patients with acute myeloid leukemia and myelodysplastic syndromes with a clinical trial specifically designed for the genetic signature of their disease. Sponsored by the National Cancer Institute, the myeloMATCH program aims to improve precision medicine.